DS
IBRX icon

David Shaw’s ImmunityBio IBRX Stock Holding History

David Shaw’s Portfolio IBRX Stock Details IBRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$101M Sell
11,551,019
-1,020,578
-8% -$7.72M 0.05% 443
2026
Q1 		$96.4M Buy
+12,571,597
New +$86.1M 0.06% 394
2025
Q3 		– Sell
-237,147
Closed -$626K – 4724
2025
Q2 		$626K Buy
+237,147
New +$638K ﹤0.01% 3535
2024
Q4 		– Sell
-520,053
Closed -$1.93M – 4591
2024
Q3 		$1.93M Buy
+520,053
New +$2.41M ﹤0.01% 2738
2024
Q2 		– Sell
-236,634
Closed -$1.27M – 4631
2024
Q1 		$1.27M Sell
236,634
-354,467
-60% -$1.61M ﹤0.01% 2930
2023
Q4 		$2.97M Buy
+591,101
New +$1.85M ﹤0.01% 2343
2022
Q4 		– Sell
-678,504
Closed -$3.37M – 4965
2022
Q3 		$3.37M Buy
678,504
+267,827
+65% +$1.22M ﹤0.01% 2505
2022
Q2 		$1.53M Buy
410,677
+315,409
+331% +$1.27M ﹤0.01% 3305
2022
Q1 		$534K Sell
95,268
-235,233
-71% -$1.44M ﹤0.01% 4328
2021
Q4 		$2.01M Sell
330,501
-46,969
-12% -$353K ﹤0.01% 3358
2021
Q3 		$3.68M Buy
377,470
+293,098
+347% +$3.23M ﹤0.01% 2416
2021
Q2 		$1.21M Buy
+84,372
New +$1.39M ﹤0.01% 3384
2020
Q4 		– Sell
-42,661
Closed -$296K – 4018
2020
Q3 		$296K Buy
+42,661
New +$425K ﹤0.01% 3450
2019
Q3 		– Sell
-13,200
Closed -$13K – 3899
2019
Q2 		$13K Sell
13,200
-1,508
-10% -$1.74K ﹤0.01% 3624
2019
Q1 		$23K Sell
14,708
-165,887
-92% -$208K ﹤0.01% 3536
2018
Q4 		$210K Buy
180,595
+139,431
+339% +$319K ﹤0.01% 3524
2018
Q3 		$152K Sell
41,164
-15,432
-27% -$48.8K ﹤0.01% 3589
2018
Q2 		$174K Buy
56,596
+15,787
+39% +$58.5K ﹤0.01% 3576
2018
Q1 		$159K Buy
40,809
+28,781
+239% +$126K ﹤0.01% 3360
2017
Q4 		$54K Buy
+12,028
New +$57K ﹤0.01% 3531

Other funds holding IBRX

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Two Sigma Investments
Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Millennium Management
Millennium Management New York $276B AUM 44.8% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $860B AUM 41.15% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return

David Shaw's IBRX Position: Q2 2026 in Review

David Shaw reduced its ImmunityBio (IBRX) stake by 8.1% in Q2 2026, selling an estimated $7.72M and leaving 11,551,019 shares worth $101M. The position accounts for 0.05% of the portfolio, ranked #443.

David Shaw first reported a position in IBRX in Q4 2017 and has held it in 20 quarters since. 402 funds tracked by Wall St. Rank hold IBRX as of Q2 2026.

  • David Shaw held 11,551,019 shares of ImmunityBio worth $101M as of Q2 2026.
  • David Shaw sold 1,020,578 ImmunityBio shares in Q2 2026, an estimated $7.72M.
  • ImmunityBio made up 0.05% of David Shaw's portfolio in Q2 2026, its #443 holding.
  • David Shaw first reported a position in ImmunityBio in Q4 2017 and has held it in 20 quarters since.
  • 402 funds tracked by Wall St. Rank held ImmunityBio as of Q2 2026.

Based on D.E. Shaw & Co's 13F filing for Q2 2026, filed 14 Aug 2026.